The Swiss pharmaceutical group pursues its strategy in China. After announcing yesterday a $ 1 billion in the country's R & D, he bought 85% of private vaccine manufacturer Zhejiang Tianyuan Bio-Pharmaceutical. A transaction amounting to 125 million dollars (in cash). Novartis facilitates the penetration of its products on the third global vaccine market (over $ 1 billion in 2008), which is expected to soon grow to double digits. In China, its presence was previously limited to vaccines against influenza and rabies.
Came in 1994 on the vaccine market, Zhejiang Tianyuan owns a portfolio products against bacterial and viral diseases. The Chinese lab has developed such a vaccine against hemorrhagic fever with renal syndrome (HFRS). In 2008 he recorded a turnover of $ 25 million (doubled compared to 2006).
0 comments:
Post a Comment